Aldo Magnini has been appointed managing director of Clariant's pharmaceuticals ingredients manufacturing business in Italy, based around the company's two manufacturing plants in Origgio and Isso. Dr Magnini joins Clariant from Cambrex Profarmaco, where he served as vice president of sales and marketing.
Origgio/Isso is one of two main centres for current Good Manufacturing Practice that Clariant operates for the commercial manufacture of active pharmaceuticals, with the other located in Springfield, Missouri, USA. Smaller-scale cGMP facilities are also operated in the UK and France.
Dr Magnini will direct and manage all Clariant's pharmaceuticals activities within Italy, with responsibility for the manufacturing and development capabilities of APIs, antivirals, quinolones, nucleosides and veterinary medicines.
Ralf Pfirmann, global business director for pharmaceutical market management at the group, said that the appointment of Dr Magnini was in line with Clariant's commitment to strengthen its Italian resources "to serve cGMP customers better in the future."
Meanwhile, in Clariant's latest LIFE newsletter for the pharmaceutical business, Dr Pfirmann noted that the company will be investing heavily in its process R&D capabilities over the remainder of 2003, with "a substantial addition in personnel and facilities to this important area."